Recombinant Mouse Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (Dad1)

What is DAD1 and what is its primary biological role?

DAD1 (Defender Against Cell Death 1) was initially discovered in BHK21 cells as a negative regulator of programmed cell death, which is a process essential for normal organism development and tissue homeostasis . Subsequent studies revealed that DAD1 serves as a subunit of the mammalian oligosaccharyltransferase (OST) complex, where it is required for both the functional activity and structural integrity of this complex . The OST complex plays a critical role in N-linked glycosylation, a fundamental post-translational modification of proteins.

Unlike the inhibitor of apoptosis proteins (IAP) family, DAD1 does not contain any baculoviral IAP repeat (BIR) domains, indicating it operates through different mechanisms to regulate cell death . Alternative names for DAD1 include DAD-1, oligosaccharyl transferase subunit DAD1, and dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1, reflecting its role in glycosylation processes .

How does DAD1 function in N-linked glycosylation?

DAD1 functions as a non-catalytic component of the oligosaccharyltransferase complex, which is responsible for the transfer of oligosaccharide moieties to nascent polypeptides in the process of N-linked glycosylation . This complex is located in the endoplasmic reticulum and catalyzes a critical step in the biosynthesis of N-linked glycoproteins.

Studies using mouse models have demonstrated that the absence of DAD1 leads to the expression of abnormal N-linked glycoproteins . This abnormality in glycosylation is likely due to compromised structural integrity and function of the OST complex in the absence of DAD1. The connection between DAD1 and glycosylation is further supported by research showing that tunicamycin (an inhibitor of N-linked oligosaccharide biosynthesis) and PNGase F (an enzyme that cleaves N-linked glycans) produce effects similar to those observed with DAD1 depletion .

Methodologically, researchers can assess DAD1's role in glycosylation by analyzing cell surface glycans using fluorescently labeled lectins such as Concanavalin A (ConA) and Lens Culinaris agglutinin (LCA), which detect specific glycan structures affected by alterations in N-glycosylation pathways .

What phenotypes are observed in DAD1-deficient mouse models?

Mouse models with DAD1 deficiency exhibit several distinct phenotypes that highlight the critical role of this protein in development:

• Embryonic lethality: Homozygous Dad1 null mice do not survive beyond embryonic day 10.5 .

• Developmental delay: By embryonic day 7.5, Dad1-deficient embryos show significant developmental delay compared to wild-type counterparts .

• Aberrant morphology: The mutant embryos display abnormal morphological features, including impaired mesodermal development .

• Increased apoptosis: Specific tissues in Dad1-deficient embryos exhibit elevated levels of apoptosis .

• Glycosylation defects: The mutant embryos express abnormal N-glycosylated proteins, consistent with DAD1's role in the oligosaccharyltransferase complex .

• Failure to turn the posterior axis: This specific developmental defect precedes the eventual lethality observed in these embryos .

These findings collectively establish that DAD1 is essential for proper N-linked glycoprotein processing and cell survival during mouse embryonic development. The methodological approach of generating and analyzing null alleles for Dad1 has been instrumental in elucidating these in vivo functions.

What are the optimal conditions for storing and handling recombinant DAD1 protein?

The stability and activity of recombinant DAD1 protein are significantly influenced by storage conditions. Based on technical information for similar recombinant proteins:

• Temperature considerations:

  • For long-term storage, maintain the protein at -20°C/-80°C .

  • The shelf life of liquid formulations is approximately 6 months at -20°C/-80°C .

  • Lyophilized forms offer extended stability, with a shelf life of up to 12 months at -20°C/-80°C .

• Freeze-thaw cycles:

  • Repeated freezing and thawing is not recommended as it may compromise protein integrity .

  • For working stocks, store aliquots at 4°C for up to one week to minimize freeze-thaw damage .

• Reconstitution protocol:

  • Briefly centrifuge the vial prior to opening to bring contents to the bottom .

  • Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL .

  • For optimal stability, add glycerol to a final concentration of 5-50% (with 50% being typical) before aliquoting for long-term storage .

The methodological approach to preserving protein activity involves careful consideration of buffer composition, temperature, and minimizing physical stresses that could lead to denaturation or aggregation.

How can researchers validate the functionality of recombinant DAD1 in experimental systems?

Validating the functionality of recombinant DAD1 protein in experimental systems requires multiple approaches:

• Structural integrity assessment:

  • SDS-PAGE analysis with expected molecular weight confirmation (typically appearing around 12-15 kDa) .

  • Purity verification (>85% purity is standard for research applications) .

• Functional assays:

  • N-glycosylation activity: Monitor the glycosylation status of known N-glycosylated proteins (such as LOX) in the presence vs. absence of DAD1 .

  • Lectin binding assays: Use fluorescently labeled lectins (ConA and LCA) to detect changes in cell surface glycans when DAD1 is present or depleted .

  • Blocking assays: The recombinant protein can be used in blocking assays to validate antibody specificity .

• Complementation studies:

  • Introduction of recombinant DAD1 into Dad1-null cells should rescue the glycosylation defects and potentially reduce apoptosis if the protein is functional.

  • When using tagged versions of the protein, researchers should verify that the tag does not interfere with function .

• Interaction studies:

  • Co-immunoprecipitation to confirm proper integration into the oligosaccharyltransferase complex.

  • Analysis of interaction with other OST complex components to ensure proper protein-protein interactions.

These methodological approaches provide complementary data on both the structural integrity and functional capacity of recombinant DAD1 protein preparations.

What experimental systems are most suitable for studying DAD1 function?

Several experimental systems have proven valuable for investigating DAD1 function:

• Cell culture models:

  • BHK21 cells: The original cell line in which DAD1 was discovered as an anti-apoptotic factor .

  • Cancer cell lines: MDA-MB-231 and U87 cells have been used successfully to study the role of OST complex components in glycosylation .

  • These cell lines show regulated expression of DAD1-dependent glycoproteins and can be manipulated under various conditions such as hypoxia, which enhances expression of proteins like LOX that serve as readouts for N-glycosylation .

• Mouse models:

  • Dad1 knockout mice provide critical insights into the in vivo function of this protein during development .

  • Heterozygous Dad1 mice can be valuable for studying partial loss-of-function effects.

• Yeast systems:

  • Saccharomyces cerevisiae has been used to study the role of Dad1 in regulating N-linked glycosylation and apoptotic cell death .

  • Yeast expression systems are also used to produce recombinant DAD1 protein for functional studies .

• CRISPR/Cas9 gene editing:

  • Modern gene editing approaches allow for precise manipulation of Dad1 in various cell types .

  • sgRNAs targeting different genomic regions of Dad1 or related genes like DDOST have been effective in creating cellular models with altered glycosylation pathways .

The methodological decision regarding which experimental system to use should be guided by the specific research question, with consideration of species-specific differences in glycosylation pathways and DAD1 function.

What molecular mechanisms connect DAD1's roles in glycosylation and apoptosis regulation?

The dual function of DAD1 in both glycosylation and apoptosis regulation represents an intriguing intersection of cellular processes. Current evidence suggests several potential mechanisms linking these functions:

• Glycosylation-dependent survival signaling:

  • N-linked glycosylation affects the folding, stability, and function of numerous cell surface receptors and signaling molecules involved in cell survival pathways.

  • DAD1-mediated proper glycosylation may be required for the correct functioning of these survival-promoting proteins.

• ER stress response:

  • Defective N-glycosylation triggers endoplasmic reticulum (ER) stress, which can lead to apoptosis via the unfolded protein response (UPR).

  • In Dad1-deficient embryos, increased apoptosis is observed in specific tissues, suggesting tissue-specific sensitivity to disruptions in N-glycosylation .

  • The embryonic lethality by day 10.5 in Dad1-null mice may result from cumulative ER stress due to improper protein glycosylation .

• Direct anti-apoptotic function:

  • While DAD1 lacks the characteristic BIR domains found in canonical inhibitor of apoptosis proteins , it may still have direct interactions with components of the apoptotic machinery.

  • The fact that DAD1 overexpression is observed in some human hepatocellular carcinomas suggests it may provide a survival advantage to cancer cells beyond its glycosylation function .

Methodologically, distinguishing between direct anti-apoptotic functions and indirect effects via glycosylation requires careful experimental design, such as creating DAD1 mutants that retain one function but lose the other, or by temporally separating glycosylation defects from apoptotic events through inducible expression systems.

How does DAD1 contribute to developmental processes during embryogenesis?

DAD1 plays a critical role in embryonic development, as evidenced by the severe phenotypes observed in Dad1-null mice:

• Mesodermal development:

  • Dad1-deficient embryos show impaired mesodermal development by embryonic day 7.5 .

  • This suggests that DAD1-dependent glycosylation is particularly important for signals regulating mesoderm formation and differentiation.

• Posterior axis formation:

  • A specific defect observed in Dad1-null embryos is their failure to turn the posterior axis .

  • This morphogenetic process requires complex cell movements and tissue remodeling, which may depend on properly glycosylated adhesion molecules and extracellular matrix components.

• Tissue-specific apoptosis:

  • The increased levels of apoptosis in Dad1-deficient embryos occur in specific tissues rather than throughout the embryo .

  • This tissue specificity suggests differential requirements for DAD1 function across developing tissues, possibly reflecting varying dependencies on particular glycoproteins.

• Temporal aspects:

  • Dad1-null embryos develop normally until around E7.5 before showing developmental delays and defects .

  • This timing may correspond to a developmental stage when maternal DAD1 protein or mRNA is depleted, or when specific DAD1-dependent glycoproteins become critical for development.

Methodologically, techniques such as tissue-specific conditional knockouts, lineage tracing combined with apoptosis markers, and glycoproteomic analysis of affected tissues would provide further insights into the developmental roles of DAD1.

What is the potential role of DAD1 in carcinogenesis and cancer progression?

Several lines of evidence suggest DAD1 may play significant roles in cancer biology:

• Overexpression in hepatocellular carcinoma:

  • DAD1 mRNA overexpression has been reported in some human hepatocellular carcinomas .

  • This suggests DAD1 may provide advantages to cancer cells, potentially through enhanced glycosylation capacity or direct anti-apoptotic effects.

• Glycosylation alterations in cancer:

  • Altered glycosylation patterns are a hallmark of cancer cells, affecting processes including immune evasion, metastasis, and drug resistance.

  • As a component of the oligosaccharyltransferase complex, DAD1 may contribute to these cancer-associated glycosylation changes.

• Resistance to apoptosis:

  • Cancer cells typically develop mechanisms to evade apoptosis.

  • DAD1's role as a negative regulator of programmed cell death suggests it could potentially be exploited by cancer cells to enhance survival.

• Hypoxia adaptation:

  • Hypoxic conditions in tumors induce expression of proteins like LOX, which require N-glycosylation for proper function .

  • DAD1-mediated glycosylation may be particularly important under these stress conditions common in the tumor microenvironment.

Methodologically, approaches to study DAD1 in cancer contexts include: comparative expression analysis across tumor types and stages; functional studies using cancer cell lines with DAD1 knockdown or overexpression; analysis of glycosylation patterns in tumors with varying DAD1 levels; and investigation of DAD1's potential as a therapeutic target using selective inhibitors of the OST complex.

What techniques are most effective for analyzing N-linked glycosylation changes related to DAD1 function?

Several complementary techniques can effectively characterize glycosylation changes related to DAD1 function:

• Protein migration analysis:

  • SDS-PAGE followed by western blotting for specific glycoproteins can reveal shifts in apparent molecular weight due to altered glycosylation .

  • For example, LOX has been used as a reporter protein, showing reduced apparent mass when N-glycosylation is inhibited by tunicamycin or when treated with PNGase F .

• Glycan-specific lectin binding:

  • Fluorescently labeled lectins with distinct glycan binding preferences provide valuable tools:

    • Concanavalin A (ConA) detects α-linked mannose structures

    • Lens Culinaris agglutinin (LCA) detects both α-linked mannose and core fucosylated N-glycans

  • Flow cytometry analysis of lectin binding to cells with various DAD1 expression levels can quantify changes in surface glycan patterns.

• Enzymatic deglycosylation:

  • Comparing protein mobility before and after treatment with glycosidases like PNGase F helps confirm the presence and extent of N-glycosylation .

  • Different glycosidases with distinct specificities can reveal the types of glycans affected by DAD1 alterations.

• Mass spectrometry:

  • Glycoproteomic approaches can provide detailed structural information about the glycans affected by DAD1 deficiency.

  • Site-specific glycan analysis can identify which glycosylation sites on target proteins are most dependent on DAD1 function.

• Genetic manipulation approaches:

  • CRISPR/Cas9-mediated gene editing with sgRNAs targeting DAD1 or other OST complex components provides a clean system for studying glycosylation changes .

  • The comparison between non-targeting controls and DAD1-targeted cells reveals DAD1-specific effects.

The methodological principle underlying effective glycosylation analysis is the combination of multiple complementary techniques to build a comprehensive understanding of how DAD1 affects the glycoproteome.

How can researchers accurately distinguish between DAD1's direct effects on apoptosis versus indirect effects via altered glycosylation?

Distinguishing between direct anti-apoptotic functions and glycosylation-mediated effects requires sophisticated experimental approaches:

• Structure-function analysis:

  • Generate DAD1 mutants that retain OST complex integration but lose anti-apoptotic function (or vice versa).

  • Perform complementation studies in Dad1-null cells to determine which functions can be independently rescued.

• Temporal separation approaches:

  • Use inducible expression systems to rapidly modulate DAD1 levels and monitor glycosylation and apoptotic responses over time.

  • If apoptotic effects precede detectable glycosylation changes, this would suggest direct anti-apoptotic functions.

• Comparative OST complex manipulations:

  • Target different OST complex components (not just DAD1) and compare apoptotic phenotypes.

  • If only DAD1 depletion triggers apoptosis while other components primarily affect glycosylation, this would support direct anti-apoptotic roles.

• Bypass experiments:

  • Artificially maintain proper glycosylation through alternative means in DAD1-deficient cells.

  • Determine if apoptosis still occurs despite restored glycosylation.

• Protein interaction studies:

  • Investigate direct binding partners of DAD1 beyond the OST complex.

  • Identify potential interactions with apoptotic regulatory proteins that could explain direct effects.

These methodological approaches should be complemented by careful quantification of both glycosylation status and apoptotic markers to establish causal relationships between DAD1 function and cellular outcomes.